GlaxoSmithKline CEO Jean-Pierre Garnier has been ordered by a U.S. district court magistrate judge in California to answer questions in a lawsuit brought against the company over its patent on the HIV antiretroviral drug Retrovir (AZT), AFX News reports. The lawsuit, filed by Los Angeles-based AIDS Healthcare Foundation, seeks to block the company's patent, claiming that the drug was developed by the National Institutes of Health with federal money in 1964 as a cancer drug. Under U.S. law, drugs developed with federal money must be sold at a reasonable price, which can be set by the courts. The lawsuit claims that because AZT was developed with NIH funds, the medication--and combination pills Combivir and Trizivir, which include AZT--should be sold at far cheaper rates. Garnier answered questions in a deposition in January, but AHF attorneys pressed for more questioning.
Search
AI Powered
Human content,
AI powered search.
Latest Stories
Stay informed on important LGBTQ+ news.
Sign up for our email newsletter.
@ 2026 Equal Entertainment LLC.
All rights reserved
All rights reserved
By continuing to use our site, you agree to our Privacy Policy and Terms of Use.
The Latest
More For You
Most Popular
@ 2026 Equal Entertainment LLC. All Rights reserved















